BioSpace News Archive

Lightspeed Microscopy, Inc., an end-to-end 3D pathology platform, announced today it has raised $4 million in a Series A financing round.

Today, the U.S. Food and Drug Administration approved StrataGraft for the treatment of adult patients with thermal burns containing intact dermal elements (remaining deep skin layers) for which surgical intervention is clinically indicated (also referred to as deep partial thickness burns)

SpringWorks Therapeutics, Inc. announced that an update on the previously reported interim data from the first 20 adult patients enrolled in the ongoing Phase 2b ReNeu trial evaluating mirdametinib, an investigational MEK inhibitor being studied in adult and pediatric patients with NF1-associated plexiform neurofibromas, was presented at the 2021 Children’s Tumor Foundation NF Conference being held June 14-16, 2021.

SI-BONE, Inc., a Silicon Valley-based medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy announced that the French Health Ministry has granted national reimbursement for the iFuse-3D Implant System™.

Medexus Pharmaceuticals Inc. announced that it has received final approval for listing of the Company’s common shares on the Toronto Stock Exchange.

Janux Therapeutics, Inc. today announced the closing of its previously announced initial public offering of 13,110,000 shares of its common stock.

PURE Bioscience, Inc. today reported financial results for the fiscal third quarter and nine-month period ended April 30, 2021.

Baxter International Inc. will host a conference call to discuss its second-quarter 2021 financial results on Thursday, July 29, 2021 at 7:30 a.m. Central Time.

MedX Health Corporation a global leader in teledermatology, is pleased to announce a distribution agreement with VidaCeuticals Health Products Inc. that will see MedX’s integrated skin assessment teledermatology platform offered at four clinics in Ontario beginning in late June, with plans for a broader market roll-out in Canada and the United States later this year.

Camurus AB (NASDAQ STO: CAMX) today announced that its US licensee Braeburn has resubmitted the New Drug Application (NDA) for Brixadi 1 (buprenorphine) extended-release weekly and monthly injections for the treatment of moderate to severe opioid use disorder to the US Food and Drug Administration (FDA).